Personalis Inc (OQ:PSNL)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 6600 Dumbarton Circle
FREMONT CA 94555
Tel: N/A
Website: https://www.personalis.com
IR: See website
<
Key People
Christopher M. Hall
President, Chief Executive Officer, Director
Aaron Tachibana
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Richard Chen
Executive Vice President - Research and Development, Chief Medical Officer
Stephen Moore
Vice President, General Counsel, Corporate Secretary
   
Business Overview
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company's advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company's tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Financial Overview
For the fiscal year ended 31 December 2023, Personalis Inc revenues increased 13% to $73.5M. Net loss decreased 4% to $108.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling, general, and administrative decrease of 18% to $42.3M (expense), Stock-based Compensation in SGA decrease of 39% to $7.4M (expense).
Employees: 223 as of Jan 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $73.48M as of Dec 31, 2023
EBITDA (TTM): -$84.94M as of Dec 31, 2023
Net annual income (TTM): -$108.30M as of Dec 31, 2023
Free cash flow (TTM): -$67.17M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 50,503,889 as of Feb 22, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.